In diabetic hearts, deficiency of myeloid MR signalling inhibited gene expression of a marker of cardiac hypertrophy (Myh7) and reduced cardiomyocyte size [20] while preventing loss of capillaries and expression of genes required for vascularisation (Vegfa and Pdgfb) [21–23], which suggests a role for myeloid MR signalling in diabetic cardiomyopathy. This evidence concerns the gene NR3C2 and cardiac hypertrophy.